International Myositis Society - Special Newsletter March 2026
The new Myositis issue for 2026 is online!
Read it now and click HERE
All individual articles are also listed and individually linked below.
Idiopathic inflammatory myopathies: one year in review 2025 M. Diomedi, F. Fattorini, S. Aliberti, L.M. Bianchessi, A. Castellucci, J. Schmidt, L. Cavagna, L. Carli, S. Barsotti Shared governance of international myositis networks T. Liewluck, L.G. Rider, K. Cheng, H. Chinoy, M.M. Dimachkie, E. Dourado, P.C. Gandiga, D.A. Isenberg, K. Ardalan, S. Keret, S. Kim, P. Korsten, I.E. Lundberg, P.M. Machado, F.W. Miller, C. Papadopoulou, S. Rosina, L.A. Saketkoo, S. Schlüter, J. Vencovský, A.J. Van Der Kooi, J. Schmidt The MicroIBioM study: the gut microbiome in inclusion body myositis M. Winkler, W. Seel, C. Kornblum, M.-C. Simon, J. Reimann Comparison of pre- and post-natal environmental exposures in United States versus Brazilian patients with juvenile dermatomyositis Predictors of thrombotic events in patients with idiopathic inflammatory myopathies Analysis of clinical features and risk factors for patients with idiopathic inflammatory myopathy complicated by Pneumocystis jirovecii pneumonia Pneumocystis jirovecii pneumonia in anti-MDA5-positive dermatomyositis: characterisation, risk factors and prognosis Cardiac involvement in patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis Short Form 36 (SF-36) health survey questionnaire in health-related quality of life assessment in patients with inflammatory myopathies Prevalence and early detection of myocarditis in idiopathic inflammatory myopathies: a prospective single-centre study Clinical phenotypes and long-term outcomes of anti-SRP versus anti-HMGCR immune-mediated necrotising myopathy: a 13-year single-centre study Peripheral blood immunophenotypic diversity in patients with anti-MDA5+ dermatomyositis and its impact on prognosis Assessment of myositis specific antibodies in primary chronic arthritis: single centre prospective study Alterations of mucosal-associated invariant T cells in dermatomyositis Health-related quality of life improvements and response thresholds of myositis outcome measures and response criteria The Refractory DermatoMyositis Index (ReDMI): a clinical tool to predict refractory disease in patients with dermatomyositis Janus kinase inhibitors therapy in idiopathic inflammatory myopathies: a case series Potential pitfalls in the differential diagnosis of myositis versus hereditary myopathies Factors associated with endomysial fibrosis in anti-signal recognition particle antibody immune-mediated necrotising myopathy Cardiac involvement in newly diagnosed patients with idiopathic inflammatory myopathies is associated with skeletal muscle involvement Validation of simplified scoring systems for assessing cutaneous disease activity in dermatomyositis Recurrent and new primary cancer risk in adult patients with idiopathic inflammatory myositis and a history of malignancy Fitbit as an activity monitor in idiopathic inflammatory myopathy: results from a real-world cohort Non-inflammatory mimickers of myositis: a guide for rheumatologists Shaping the landscape of interstitial lung disease in idiopathic inflammatory myopathies: state of the art, evidence gaps and a need for clinical trials D. Rivero Gallegos, F.M. Pais, T. Lan, C. Papadopoulou, E.K. Joerns, J. Paul, J. Rojas Serrano, T. Kulkarni, P.C. Gandiga, H. So, K. Houghton, N. Bagri, M. Jansen, B. Bader Meunier, E.M. Wilfong, R. Aggarwal, R.W. Hallowell, V. Nagaraja Pain in myositis: prevalence, assessment, potential mechanisms and considerations for management Mitochondrial abnormalities in idiopathic inflammatory myopathies Treatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis Association of NXP2 autoantibodies with a more severe clinical phenotype of juvenile dermatomyositis Successful therapy of refractory dermatomyositis skin rash with anifrolumab Statins and ribociclib interaction induced necrotising myopathy: a case report and literature review F. Torri, G. Vadi, G. Aringhieri, G. Alì, F. Siciliano, G. Ricci, G. Siciliano Comment on: Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study by You et al .W. Rojas-Zuleta Comment on: Successful management of pulmonary hypertension with baricitinib in a dermatomyositis patient C. Pinto Oliveira, M.D. Pascoal, A.R. Prata, D. Carvalho, M.G. Castro, E. Dourado Reply to the comment on: Successful management of pulmonary hypertension with baricitinib in a dermatomyositis patient C. Rizzo, L. La Barbera, G. Guggino Efficacy of rituximab treatment in a post-COVID-19 vaccine myositis overlapping to systemic sclerosis: a histological follow-up F. Bandinelli, G. Dallagiacoma, F. Nozzoli, M. Capassoni, R. Nassini Neutrophil-to-lymphocyte ratio as a prognostic indicator in anti-MDA5 dermatomyositis with interstitial lung disease and its link to IFN-α and IL-6 Y. Endo, T. Koga, Y. Mizunoo, T. Shimizu, N. Sakamoto, A. Kawakami Comment on: Cancer-associated myositis before and after the COVID-19 pandemic onset F.M. Costa, R. Campanilho-Marques, E. Dourado, M. Bandeira, B. Correia, A.T. Melo, F. Saraiva, S.C. Barreira, J.E. Fonseca Reply to the comment on: Cancer-associated myositis before and after the COVID-19 pandemic onset H. Daungsupawong, V. Wiwanitkit Dermatomyositis assessment of rash via telemedicine: a preliminary study N. Pongtarakulpanit, A. Bishnoi, D.P. Ascherman, S. Moghadam-Kia, C.V. Oddis, R. Aggarwal Complete clinical and serological remission of anti-synthetase syndrome after autologous haematopoietic stem cell transplantation V. Ruiz-Esquide, S. Prieto-Gonzalez, E. Ruiz-Ortiz, C. Arnaldos Acquired generalised lipodystrophy as an uncommon complication of anti-Mi-2 dermatomyositis: a case report A. Bustos-Merlo, M. Martín-Armada, M. Zamora-Pasadas, I. Sánchez-Berná, N. Navarrete-Navarrete
Follow iMyoS on social media
